Hi-C analysis revealed BCL2 rearrangements, losses of CDKN2A, CDKN2B, and TNFAIP3, and a complex genome profile, supporting a high-risk DLBCL diagnosis and suggesting potential benefit from targeted clinical trials to enhance treatment outcomes. This evidence concerns the gene CDKN2A and diffuse large B-cell lymphoma.